Statistical & Clinical Analysis
French TMA Score: Two Laboratory Criteria and Limits of Interpretation
Explore the two-point French score described by the French TMA reference center using platelet count and serum creatinine, with explicit units, thresholds and clinical limitations.
What the two-point score counts
The French TMA reference center’s 2023 protocol presents a French score with two laboratory items, each worth one point: platelet count below 30 × 10⁹/L, and serum creatinine below 2.26 mg/dL. The resulting total ranges from 0 to 2. The example below implements those exact units and strict cutoffs.
Coppo and colleagues’ 2010 research also investigated antinuclear antibodies along with platelet count and creatinine. Adding a third ANA point would define a different version and must not be mixed with the two-point reference-center table or its reported outcomes.
Boundaries and units matter
The reference-center table specifies less than 30 and less than 2.26, so exactly 30 × 10⁹/L or exactly 2.26 mg/dL does not receive a point in this example. The original 2010 report describes creatinine at or below 200 µmol/L and uses less-than versus less-than-or-equal wording for platelet 30 in different passages. These statements should not be silently treated as identical at the boundary.
Enter platelet count in ×10⁹/L and creatinine in mg/dL; a value in µmol/L must be converted using an appropriate laboratory conversion before using the example. Around the cutoff, rounding and the chosen published version matter.
Spreadsheet example
B2 holds platelet count in ×10⁹/L, B3 holds creatinine in mg/dL, and B4 calculates the number of matching criteria. Both values must be numeric; platelet count must be nonnegative and creatinine positive. For example, 14 and 1.2 give 2 points.
=IF(OR(NOT(ISNUMBER(B2)),NOT(ISNUMBER(B3))),"Enter valid platelet count and creatinine",IF(OR(B2<0,B3<=0),"Enter valid platelet count and creatinine",IF(B2<30,1,0)+IF(B3<2.26,1,0)))Scope and clinical interpretation
The score was developed for specific patients with thrombotic microangiopathy; the reference-center protocol describes relevant clinical context and limitations, including associated conditions. It is not a general screening tool and cannot establish or rule out TTP, distinguish all causes of microangiopathy, or replace an ADAMTS13 assay or specialist assessment.
Suspected TTP can be a medical emergency. The numeric example does not diagnose, recommend a treatment, or decide whether treatment may be delayed; clinicians must consider the full presentation and current guidance. Reported proportions in a research cohort should not be read as guaranteed individual probabilities.
Try the example
Use the original values or change them to test your understanding.